Active, Not Recruiting
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
NCT05490771
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +20 more
- Locations
-
- ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States